APA (7th ed.) Citation

Z, Y., Y, X., W, L., S, K., H, T., S, G., . . . X, F. (2024). FDA-Approved Tedizolid Phosphate Prevents Cisplatin-Induced Hearing Loss Without Decreasing Its Anti-tumor Effect. Journal of the Association for Research in Otolaryngology : JARO, 25(3), 259. https://doi.org/10.1007/s10162-024-00945-2

Chicago Style (17th ed.) Citation

Z, Yao, et al. "FDA-Approved Tedizolid Phosphate Prevents Cisplatin-Induced Hearing Loss Without Decreasing Its Anti-tumor Effect." Journal of the Association for Research in Otolaryngology : JARO 25, no. 3 (2024): 259. https://doi.org/10.1007/s10162-024-00945-2.

MLA (9th ed.) Citation

Z, Yao, et al. "FDA-Approved Tedizolid Phosphate Prevents Cisplatin-Induced Hearing Loss Without Decreasing Its Anti-tumor Effect." Journal of the Association for Research in Otolaryngology : JARO, vol. 25, no. 3, 2024, p. 259, https://doi.org/10.1007/s10162-024-00945-2.